Lorvas SR Tablet contains Indapamide 1.5 mg, a thiazide-like diuretic primarily indicated for the management of hypertension and edema associated with congestive heart failure, hepatic cirrhosis, and renal disorders. Indapamide acts by inhibiting sodium and chloride reabsorption in the distal convoluted tubules of the nephron, promoting diuresis and reducing plasma volume, which consequently lowers blood pressure and decreases peripheral edema. The sustained-release formulation of Lorvas SR ensures a gradual and prolonged therapeutic effect, enhancing patient compliance and minimizing fluctuations in plasma drug levels. This medication is typically administered once daily, with dosage adjustments based on clinical response and patient tolerance. Common adverse effects may include electrolyte imbalances such as hypokalemia, hyponatremia, and hypercalcemia, as well as dizziness, hypotension, and gastrointestinal disturbances. Regular monitoring of electrolytes, renal function, and blood pressure is recommended during therapy to prevent complications. Lorvas SR should be used cautiously in patients with severe renal or hepatic impairment and is contraindicated in individuals with hypersensitivity to sulfonamide-derived drugs. It is essential to inform healthcare providers of any concomitant medications to avoid potential drug interactions. Lorvas SR Tablet offers an effective and convenient option for long-term management of hypertension and fluid retention conditions.